Eyenovia is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.47 – a decrease of 9.6% over the previous week. Eyenovia employs 57 staff and has a trailing 12-month revenue of around $31,405.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.47 |
|---|---|
| 52-week range | $0.37 - $2.57 |
| 50-day moving average | $0.76 |
| 200-day moving average | $1.11 |
| Wall St. target price | $10.83 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.78 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.467 from 2024-10-07
| 1 week (2024-10-01) | -7.47% |
|---|---|
| 1 month (2024-09-06) | -5.47% |
| 3 months (2024-07-08) | -46.81% |
| 6 months (2024-04-08) | -36.02% |
| 1 year (2023-10-06) | -70.06% |
|---|---|
| 2 years (2022-10-07) | -82.96% |
| 3 years (2021-10-08) | 5.45 |
| 5 years (2019-10-08) | 3.66 |
| Revenue TTM | $31,405 |
|---|---|
| Gross profit TTM | $12.4 million |
| Return on assets TTM | -92.94% |
| Return on equity TTM | -914.66% |
| Profit margin | 0% |
| Book value | $-0.04 |
| Market Capitalization | $39.7 million |
TTM: trailing 12 months
We're not expecting Eyenovia to pay a dividend over the next 12 months.
Over the last 12 months, Eyenovia's shares have ranged in value from as little as $0.37 up to $2.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 1.741. This would suggest that Eyenovia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eyenovia, Inc. , a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co. , Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.